Portfolio data

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation

• Pre-clinical companies
• Purespring Therapeutics

Autolus Therapeutics Announces License of AUCATZYL®

iOnctura commences randomized Phase II study in metastatic uveal melanoma

• Clinical companies
• iOnctura

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

• Pre-clinical companies
• Purespring Therapeutics

OMass Therapeutics appoints Birgitte Volck as Non-Executive Director

• Pre-clinical companies
• OMass Therapeutics

Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium™

• Clinical companies
• Spur Therapeutics